for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

South Korean firm to produce 150 mln doses of Russian COVID-19 vaccine - RIDF

MOSCOW, Nov 13 (Reuters) - Russia’s sovereign wealth fund said on Friday it had inked a deal with South Korea’s GL Rapha for the biotechnology firm to produce over 150 million doses per year of the Sputnik V coronavirus vaccine.

The South Korean firm is expected to begin production next month, with a roll-out to start in January 2021, the Russian Direct Investment Fund said in a statement. The doses, produced in South Korea, will be intended for global distribution, it said.

Reporting by Polina Ivanova; editing by Richard Pullin

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up